Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 52Squamous Cell Carcinoma of Head and Neck 26Carcinoma, Non-Small-Cell Lung 26Head and Neck Neoplasms 12Colonic Neoplasms 12Neoplasm Metastasis 11Neoplasms 10Rectal Neoplasms 9Pancreatic Neoplasms 9Lung Neoplasms 9Mouth Neoplasms 6Carcinoma, Squamous Cell 6Carcinoma 6Laryngeal Neoplasms 5Hypopharyngeal Neoplasms 5Oropharyngeal Neoplasms 4Thyroid Neoplasms 3Solid Tumors 3Ovarian Neoplasms 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Pancreatic Ductal 3Breast Neoplasms 3Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Laryngeal Diseases 2mCRC 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Recurrent Skin Squamous Cell Carcinoma × Cetuximab × 90 days × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡